Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Dexketoprofen/Vitamin B vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II (WHIPLASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05001555
Recruitment Status : Recruiting
First Posted : August 12, 2021
Last Update Posted : November 30, 2021
Sponsor:
Information provided by (Responsible Party):
Laboratorios Silanes S.A. de C.V.

Brief Summary:
Phase IIIb, multicenter, prospective, randomized, double-blind study to evaluate the fixed combination of Desketoprofen / Vitamin B in the management of acute pain in patients with cervical sprain grade I-II of the Quebec scale.

Condition or disease Intervention/treatment Phase
Acute Low Back Pain Drug: Dexketoprofen/Vitamin B Drug: Dexketoprofen Phase 3

Detailed Description:
Study to evaluate the efficacy and safety of the Dexketoprofen / Vitamin B combination versus dexketoprofen for the management of acute pain secondary to post-traumatic cervical sprain grade I-II of the Quebec scale, evaluated by means of the Visual Analogue Scale (VAS). To compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire in Spanish version on days 3, 5, and 7 compare to its baseline measurement between the treatment groups. Compare the proportion of subjects requiring rescue medication during the study between treatment groups. Describe the frequency and intensity of adverse events presented during the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 174 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of the Combination Dexketoprofen / Vitamin B vs Dexketoprofen in the Treatment of Pain in Patients With Post-traumatic Cervical Sprain Grade I-II of the Quebec Scale.
Actual Study Start Date : November 29, 2021
Estimated Primary Completion Date : May 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: B Vitamins

Arm Intervention/treatment
Experimental: Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)

Group A:

Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days.

Drug: Dexketoprofen/Vitamin B
1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
Other Name: D/VitB

Active Comparator: Group B: Dexketoprofen
Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
Drug: Dexketoprofen
1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
Other Name: D




Primary Outcome Measures :
  1. Changes in pain intensity [ Time Frame: Baseline, 3, 5 and 7 days ]
    Compare changes in pain intensity measured by the visual analog scale (VAS) between treatment groups. The VAS for pain is a straight line of 10 centimeters in which one end means no pain and the other end means the worst pain imaginable.

  2. Change in the degree of disability [ Time Frame: Baseline, 3, 5 and 7 days ]
    Compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire Spanish version between the treatment groups. It includes 9 questions or items (intensity of neck pain, and sleep, pins and needles in the arms at night, duration of symptoms, lifting weights, reading and watching TV, work, social activities and driving). Each of these questions has five possible answers with a score of 0 to 4, from less to greater intensity and severity respectively.

  3. Proportion of subjects requiring rescue medication [ Time Frame: 7 days ]
    Compare the proportion of subjects requiring rescue medication during the study between treatment groups.

  4. Adverse events frequency [ Time Frame: 7 days ]
    Compare the proportion of subjects that presented an adverse event between treatment groups.

  5. Adverse events intensity [ Time Frame: 7 days ]
    Compare the intensity of adverse events presented during the study, between treatment groups.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Any sex.
  • That the subject agree to participate in the study and give your written informed consent.
  • Age> 18 years old at the beginning of the study.
  • Diagnosis of a grade I or Grade II cervical sprain on the Quebec scale of no more than 3 days.
  • Visual Analog Scale (VAS) ≥4 cm.
  • Women of childbearing potential using a contraceptive method (barrier, oral hormonal, injectable, subdermal), menopausal or surgically sterile.

Exclusion Criteria:

  • Patient in whom the drug is contraindicated for medical reasons.
  • History of allergic reaction to NSAIDs, thiamine, pyridoxine and cyanocobalamin or hypersensitivity to the components of the formula.
  • A significant history of gastrointestinal disorders (for example: Gastric Ulcer, Crohn's Disease, Ulcerative Colitis, etc.)
  • Previous treatment with opioids reported in the medical history.
  • History of inflammatory arthritis (eg rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, gout).
  • History of chronic pain (eg, fibromyalgia), metastasis, and Paget's disease.
  • History of alcohol or drug abuse in the last year according to DSM-V.
  • Clinical and radiological data of cervical sprain grade III or IV of the Quebec scale.
  • History of illness or injury for more than 6 months in the neck or cervical spine
  • Patient with symptoms of spinal cord injury (weakness, incoordination or paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, etc.)
  • History of severe acute or chronic liver failure.
  • History of moderate to severe renal failure.
  • A significant history of coagulation problems (Von Willembrand, hemophilia, vitamin K deficiency, etc.).
  • At medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver failure or mental illness or with scheduled surgical or hospital procedures.
  • History / presence of any disease or condition that, in the opinion of the Investigator, could pose a risk to the patient or confuse the efficacy and safety of the study results.
  • Oncological patients (except basal cell skin cancer) or with serious diseases that, in the opinion of the investigator, have a serious prognosis or a life expectancy of less than 1 year, as well as mental illnesses.
  • Patients with symptoms suggesting an active COVID-19 infection (ie, fever, cough, dyspnea) and / or contact in the past 14 days with a suspected or positive COVID-19 patient.
  • Patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks.
  • Patients whose participation in the study may be influenced (employment relationship with the research center or sponsor, inmates, etc.)
  • Positive pregnancy test, women who are pregnant, breastfeeding or planning a pregnancy while conducting the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05001555


Contacts
Layout table for location contacts
Contact: Jorge A González, PhD 5254883785 ext 3761 jogonzalez@silanes.com.mx
Contact: Yulia Romero-Antonio, B.S. 5554883700 ext 3777 yromero@silanes.com.mx

Locations
Layout table for location information
Mexico
Laboratorio Silanes, S.A. de C.V. Recruiting
Mexico City, Mexico, 11000
Contact: Jorge A Gonzalez, PhD    +5254883785 ext 3761    jogonzalez@silanes.com.mx   
Contact: Yulia Romero-Antonio, B.S.    5554883700 ext 3777    yromero@silanes.com.mx   
Principal Investigator: Miguel A Zurqui Ramírez, M.D.         
Principal Investigator: Adelfia Urenda Quezada, M.D.         
Principal Investigator: Ma. Dolores Alonso Martínez, M.D.         
Principal Investigator: Juan B Alcocer Herrera, M.D.         
Sponsors and Collaborators
Laboratorios Silanes S.A. de C.V.
Investigators
Layout table for investigator information
Principal Investigator: Miguel A Zurqui Ramírez, M.D Icaro Investigación en Medicina S.A. de C.V.
Principal Investigator: Adelfia Urenda Quezada, M.D Mediadvance Clinical S.A.P.I. de C.V.
Principal Investigator: Ma. Dolores Alonso Martínez, M.D CICMEX Centro de Investigación Clínica de México
Principal Investigator: Juan B Alcocer Herrera, M.D INBIOMEDyC Querétaro
Publications:

Layout table for additonal information
Responsible Party: Laboratorios Silanes S.A. de C.V.
ClinicalTrials.gov Identifier: NCT05001555    
Other Study ID Numbers: SIL-30242-III-20 (1)
First Posted: August 12, 2021    Key Record Dates
Last Update Posted: November 30, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Low Back Pain
Back Pain
Pain
Neurologic Manifestations
Dexketoprofen trometamol
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents